{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fixed+Schedule&page=11",
    "query": {
      "intervention": "Fixed Schedule",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 245,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fixed+Schedule&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fixed+Schedule&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T05:02:16.334Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01327651",
      "title": "The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Time-driven dosing",
          "type": "DRUG"
        },
        {
          "name": "Event-driven dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HIV Prevention Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 622,
      "start_date": "2011-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327651"
    },
    {
      "nct_id": "NCT04776018",
      "title": "A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed and/or Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "TAK-981",
          "type": "DRUG"
        },
        {
          "name": "Mezagitamab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab and Hyaluronidase-fihj",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2021-04-20",
      "completion_date": "2023-11-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-02",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04776018"
    },
    {
      "nct_id": "NCT01102088",
      "title": "Simultaneous Integrated Boost (SIB) in Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2010-04",
      "completion_date": "2019-06-08",
      "has_results": false,
      "last_update_posted_date": "2020-05-22",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01102088"
    },
    {
      "nct_id": "NCT06376526",
      "title": "IMMUNOPLANT for Newly Diagnosed Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Linvoseltamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dickran Kazandjian, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-08-21",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06376526"
    },
    {
      "nct_id": "NCT03768063",
      "title": "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "FAP IL2V",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Emactuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-02-28",
      "completion_date": "2028-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03768063"
    },
    {
      "nct_id": "NCT02176824",
      "title": "Chronotherapy Randomized Controlled Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Bipolar Depression",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as usual",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 13,
      "start_date": "2014-06-01",
      "completion_date": "2016-04-07",
      "has_results": false,
      "last_update_posted_date": "2019-05-30",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176824"
    },
    {
      "nct_id": "NCT05558124",
      "title": "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Vyxeos",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-02-16",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05558124"
    },
    {
      "nct_id": "NCT02350673",
      "title": "A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cergutuzumab Amunaleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2015-06-29",
      "completion_date": "2019-12-16",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02350673"
    },
    {
      "nct_id": "NCT03172936",
      "title": "Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors and Lymphomas"
      ],
      "interventions": [
        {
          "name": "MIW815",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2017-09-08",
      "completion_date": "2020-12-18",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172936"
    },
    {
      "nct_id": "NCT01480609",
      "title": "Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Retigabine / Ezogabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2011-11-30",
      "completion_date": "2012-04-24",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-10-15T05:02:16.334Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01480609"
    }
  ]
}